Moderna (MRNA) Gross Margin (2020 - 2026)

Moderna (MRNA) has reported Gross Margin for 7 consecutive years, with 35.86% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin rose 1966.0% year-over-year to 35.86% in Q2 2026; TTM through Jun 2026 was 23.38%, a 2912.0% decrease from a year earlier, with the FY2025 full-year figure at 55.35%, up 59.0% from the prior year.
• Gross Margin was 35.86% for Q2 2026 at Moderna, up from 145.5% in the prior quarter.
• Over five years, Gross Margin peaked at 92.13% in Q4 2022 and troughed at 145.5% in Q1 2026.
• A 5-year average of 29.44% and a median of 47.4% in 2024 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin sank 18342 bps in 2023 and soared 16478 bps in 2024, its largest moves.
• Over 5 years, Gross Margin stood at 92.13% in 2022, then dropped by 27 bps to 66.95% in 2023, then tumbled by 65 bps to 23.5% in 2024, then soared by 42 bps to 33.33% in 2025, then grew by 8 bps to 35.86% in 2026.
• The last three Gross Margin figures came in at 35.86% (Q2 2026), 145.5% (Q1 2026), and 33.33% (Q4 2025), per Business Quant data.